Brukinsa (Zanubrutinib)
zanubrutinib 80 mg capsule, 120 · ORAL · PBS code 13041J
AUTHORITY_REQUIREDWhat it costs
AU$7769.96 PBS-determined price per 120 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-07-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Waldenstrom macroglobulinaemia
Initial treatment
The condition must have relapsed or be refractory to at least one prior chemo-immunotherapy; or
Patient must be unsuitable for treatment with chemo-immunotherapy, defined by a Cumulative Illness Rating Scale of 6 or greater, if untreated (i.e. treatment-naive) for this condition; AND
The treatment must be the sole PBS-subsidised therapy for this condition; AND
Patient must have a World Health Organisation (WHO) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less; AND
Patient must be untreated with a Bruton's tyrosine kinase inhibitor for this condition; or
Patient must have developed intolerance to another Bruton's tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal, when treated for this condition; AND
Must be treated by a medical practitioner.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Waldenstrom macroglobulinaemia
Continuing treatment
The treatment must be the sole PBS-subsidised therapy for this condition; AND
The condition must not have progressed while receiving PBS-subsidised treatment with this drug for this condition; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
Must be treated by a medical practitioner; or
Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Sponsor: BEONE MEDICINES AUS PTY LTD ABN 23 164 802 037
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.